Cheng-Jen Ma*†‡, Ching-Wen Huang*‡§, Yung-Sung Yeh*†¶, Hsiang-Lin Tsai*§#**, Huang-Ming Hu††‡‡, I-Chen Wu††‡‡, Tian-Lu Cheng§§¶¶, Jaw-Yuan Wang*†‡§**¶¶
Oncology Research, Vol.25, No.5, pp. 673-679, 2017, DOI:10.3727/97818823455816X14786040691928
Abstract We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received
regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping. Thirteen patients with previously treated mCRC were subjected to
UGT1A1 genotyping between October 2013 and June 2015 and were administered regorafenib plus FOLFIRI
with irinotecan dose escalation. Patients with UGT1A1*1/*1 and *1/*28 genotypes were administered
180 mg/m2
of irinotecan, whereas those with the UGT1A1*28/*28 genotype were administered 120 mg/m2
of irinotecan. For all patients, the irinotecan dose was increased by 30 mg/m2 every… More >
Login
Register
